In a successful scientific collaboration, Orion Biotechnology leveraged MesenFlow’s proprietary human flow-based inflammation model to evaluate its lead CCR2 antagonist. The study demonstrated complete blockade of primary monocyte transmigration, confirming potent inhibition of a key inflammatory pathway.

The CCL2–CCR2 axis plays a central role in immune cell recruitment: during inflammation, tissues release CCL2, which binds CCR2 receptors on circulating monocytes and drives their migration from the bloodstream into affected tissues.

By combining physiologically relevant human models with real-time flow analysis, MesenFlow enables partners to generate translatable insights for next-generation therapeutics. This collaboration highlights the value of advanced human inflammatory systems in identifying superior candidates for chronic inflammatory diseases.

‍